Brivaracetam efficacy and safety in focal epilepsy.

Abstract:

:Introduction: Brivaracetam (BRV) is an analog of levetiracetam (LEV) with 15-30 times greater affinity to SV2A and greater brain permeability than LEV. These properties have stimulated interest in its clinical trial data and post-marketing experience. Areas covered: The authors provide a background on epilepsy and its treatment, discuss the racetam family of antiepileptic drugs to which BRV belongs, and then discuss BRV properties and its efficacy and tolerability in the treatment of epilepsy. Expert opinion: While preclinical data suggest a broad spectrum of efficacy, BRV is only approved for focal epilepsy. The recommended starting dose is 100 mg per day, but in the absence of urgency, it may be prudent to start at 50 mg per day, considered the lowest effective dose. There was no added benefit when BRV was used adjunctively with LEV in clinical trials. However, post-marketing data suggest that some patients may experience improved seizure control when switching from LEV. Behavioral adverse effects seemed less common than with LEV, and most patients switched to BRV after experiencing behavioral adverse effects on LEV reported improvement. Prior or anticipated intolerability to LEV is the strongest indication for BRV in clinical practice.

journal_name

Expert Rev Neurother

authors

Makke Y,Abou-Khalil B

doi

10.1080/14737175.2019.1631160

subject

Has Abstract

pub_date

2019-10-01 00:00:00

pages

955-964

issue

10

eissn

1473-7175

issn

1744-8360

journal_volume

19

pub_type

杂志文章,评审
  • Muscle trigger point therapy in tension-type headache.

    abstract::Recent evidence suggests that active trigger points (TrPs) in neck and shoulder muscles contribute to tension-type headache. Active TrPs within the suboccipital, upper trapezius, sternocleidomastoid, temporalis, superior oblique and lateral rectus muscles have been associated with chronic and episodic tension-type hea...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.138

    authors: Alonso-Blanco C,de-la-Llave-Rincón AI,Fernández-de-las-Peñas C

    更新日期:2012-03-01 00:00:00

  • Inflammatory and neuroendocrine biomarkers of prognosis after ischemic stroke.

    abstract::Stroke is the third leading cause of mortality in the USA and one of the leading causes of severe morbidity. It is important to provide stroke patients and physicians with the most accurate prognostic information to optimize care and allocation of healthcare resources. Reliable prognostic markers available during the ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.200

    authors: Katan M,Elkind MS

    更新日期:2011-02-01 00:00:00

  • Treatment of motor fluctuations in Parkinson's disease: recent developments and future directions.

    abstract::Parkinson's disease (PD) is characterized clinically by rest tremor, rigidity, bradykinesia and pathologically by degeneration of nigrostriatal dopamine neurons. Motor fluctuations (wearing off) and motor complications (dyskinesia) are common features of the long-term treatment of PD. Ongoing clinical and preclinical ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.868306

    authors: Ramirez-Zamora A,Molho E

    更新日期:2014-01-01 00:00:00

  • Emerging treatments for Alzheimer's disease for non-amyloid and non-tau targets.

    abstract:INTRODUCTION:The number of people with dementia, including Alzheimer's disease, is growing as a result of an ageing global population. Treatments available for AD only alleviate the symptoms of the disease, and are effective in some people with AD for a limited time. There is no disease-modifying treatment available, a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1326818

    authors: Khan A,Corbett A,Ballard C

    更新日期:2017-07-01 00:00:00

  • Nusinersen for the treatment of spinal muscular atrophy.

    abstract:INTRODUCTION:Spinal muscular atrophy (SMA) is an autosomal recessive degenerative neuromuscular disorder characterized by loss of spinal motor neurons leading to muscle weakness. This review article focuses on a novel antisense oligonucleotide treatment, first ever approved for SMA (nusinersen, SpinrazaTM) and describe...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2017.1364159

    authors: Chiriboga CA

    更新日期:2017-10-01 00:00:00

  • Novel therapeutic strategies using nanodrug delivery, stem cells and combination therapy for CNS trauma and neurodegenerative disorders.

    abstract::The 10th Global College of Neuroprotection and Neuroregeneration Annual Conference in collaboration with the 6th International Association of Neurorestoratology VI Intercontinental Hotel, Bucharest, Romania, 4-7 April 2013 The 10th Global College of Neuroproetction and Neuroregeneration Annual Conference together with...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2013.836297

    authors: Sharma HS,Muresanu DF,Sharma A

    更新日期:2013-10-01 00:00:00

  • Teratogenic effects of antiepileptic drugs.

    abstract::Many antiepileptic drugs (AEDs) have therapeutic applications that extend beyond epilepsy to include neuropathic pain, migraine headaches and psychiatric disorders. The risk of some AEDs has been clearly established, but for newer drugs, small sample sizes and polytherapy exposures preclude a conclusive determination ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.10.57

    authors: Hill DS,Wlodarczyk BJ,Palacios AM,Finnell RH

    更新日期:2010-06-01 00:00:00

  • Interferon-beta1b in multiple sclerosis.

    abstract::In 1993, interferon (IFN)-beta(1b) for subcutaneous injection became the first US FDA-approved immunomodulatory treatment for multiple sclerosis, a chronic inflammatory disease of the CNS. In this review of IFN-beta(1b), we first present a short introduction to multiple sclerosis and currently available therapeutics. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.3.227

    authors: Buttmann M,Rieckmann P

    更新日期:2007-03-01 00:00:00

  • Analysis of recent failures of disease modifying therapies in Alzheimer's disease suggesting a new methodology for future studies.

    abstract:INTRODUCTION:Pharmaceutical companies and the NIH have invested heavily in a variety of potential disease-modifying therapies for Alzheimer's disease (AD) but unfortunately all double-blind placebo-controlled Phase III studies of these drugs have failed to show statistically significant results supporting their clinica...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2016.1194203

    authors: Amanatkar HR,Papagiannopoulos B,Grossberg GT

    更新日期:2017-01-01 00:00:00

  • Zonisamide: newer antiepileptic agent with multiple mechanisms of action.

    abstract::Zonisamide (Zonegran, Eisai, Inc.) is a broad spectrum antiepileptic drug indicated for use as adjunctive therapy in the treatment of partial seizures. Zonisamide has multiple mechanisms of action, which may explain widespread reports of its utility in focal epilepsy and generalized epilepsy, and for nonseizure disord...

    journal_title:Expert review of neurotherapeutics

    pub_type: 历史文章,杂志文章,评审

    doi:10.1586/14737175.4.6.935

    authors: Biton V

    更新日期:2004-11-01 00:00:00

  • Electrophysiologic and immunopathologic correlates in Guillain-Barré syndrome subtypes.

    abstract::Guillain-Barré syndrome (GBS) includes demyelinating and axonal subtypes with different immunopathologic mechanisms. In acute inflammatory demyelinating polyradiculoneuropathy, segmental demyelination and conduction block are the pathological and electrophysiological correlates of muscle weakness. Slowed conductions a...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.09.43

    authors: Uncini A,Yuki N

    更新日期:2009-06-01 00:00:00

  • Valdecoxib for the management of chronic and acute pain.

    abstract::Cyclooxygenase-2 specific inhibitors have anti-inflammatory and analgesic properties, and are effective in managing a wide range of chronic and acute painful conditions such as adult rheumatoid arthritis, osteoarthritis, migraine, primary dysmenorrhea and postoperative pain. Valdecoxib, an orally administered cyclooxy...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.5.1.11

    authors: Joshi GP

    更新日期:2005-01-01 00:00:00

  • Almotriptan: a review of 20 years' clinical experience.

    abstract::Introduction: Almotriptan (ALT), a serotonin 5-HT1B/1D agonist has been used in the acute treatment of migraine with or without aura for 20 years, accumulating data on more than 15,000 patients in studies and from an estimated >150 million treated migraine attacks in daily clinical practice. The last major review of A...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1080/14737175.2019.1591951

    authors: Pascual J,Vila C

    更新日期:2019-08-01 00:00:00

  • New advances in the rehabilitation of CNS diseases applying rTMS.

    abstract::Transcranial magnetic stimulation (TMS) can directly stimulate the CNS, modifying the brain's plasticity to enhance the behavior of the paretic extremities. Studies with low-frequency repetitive TMS (rTMS) on the intact hemisphere and those with high frequencies on the affected hemisphere could increase the speed of m...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.2.165

    authors: Málly J,Stone TW

    更新日期:2007-02-01 00:00:00

  • The search for biomarkers in Parkinson's disease: a critical review.

    abstract::Parkinson's disease (PD) is a progressive neurodegenerative disorder that primarily presents with features of bradykinesia, rigidity and tremor, and has, as part of its core pathology, the degeneration of dopaminergic neurons in the substantia nigra pars compacta. There is a great need for the development of a reliabl...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.12.1841

    authors: Antoniades CA,Barker RA

    更新日期:2008-12-01 00:00:00

  • Memory problems in dementia: adaptation and coping strategies and psychosocial treatments.

    abstract::Memory problems are generally quite prominent in dementia and they have a significant impact on everyday functioning. Medication developed for Alzheimer's disease, for example, acetylcholinesterase inhibitors, can slow down the increase of cognitive impairment for a while. In addition to pharmacotherapy, psychosocial ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.167

    authors: Dröes RM,van der Roest HG,van Mierlo L,Meiland FJ

    更新日期:2011-12-01 00:00:00

  • The limited demyelinating diseases: the voyage of optic neuritis and transverse myelitis to multiple sclerosis and neuromyelitis.

    abstract::The spectrum of idiopathic inflammatory-demyelinating disorders of the CNS is classified based on clinical symptoms and signs, clinical severity, lesion distribution, neuroimaging features and cerebrospinal fluid characteristics. There is a wide variety of conditions in this broad spectrum. In some cases, the dissemin...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.6

    authors: Idiman E,Ozakbaş S

    更新日期:2011-03-01 00:00:00

  • Neural bases of emotional processing in pediatric bipolar disorder.

    abstract:UNLABELLED:Pediatric bipolar disorder (PBD) presents with severe affect dysregulation characterized by elated mood, irritability and depressive symptoms, often in the form of a mixed episode. Early recognition of the external clinical features and the underlying emotional processing circuitry will help us understand th...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.8.9.1381

    authors: Pavuluri MN,Passarotti A

    更新日期:2008-09-01 00:00:00

  • Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson's disease.

    abstract::Neuroprotective therapy has been proposed for age-related neurodegenerative disorders, including Parkinson's disease. Inhibitors of type B monoamine oxidase (MAOB-Is), rasagiline and (-)deprenyl, are the most promising candidate neuroprotective drugs. Clinical trials of rasagiline in patients with Parkinson's disease ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/ern.09.68

    authors: Naoi M,Maruyama W

    更新日期:2009-08-01 00:00:00

  • Fentanyl for breakthrough pain: a systematic review.

    abstract::The purpose of this article is to systematically review the use of fentanyl as an analgesic for breakthrough pain. This article found that the oral transmucosal fentanyl (OTFC) had a quicker onset to analgesia than oral immediate-release opioids. Intranasal fentanyl (INFS) had a quicker onset to analgesia than buccal ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/ern.11.63

    authors: Davis MP

    更新日期:2011-08-01 00:00:00

  • Adverse effects in the treatment of Parkinson's disease.

    abstract::Side effects to antiparkinsonian drugs constitute an important component of the daily management of patients with Parkinson's disease. Treatment with levodopa frequently leads to motor fluctuations and dyskinesias. Hallucinosis, nausea and vomiting, drowsiness, orthostatic hypotension and peripheral edema can be manag...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1586/14737175.2.1.105

    authors: Singer C

    更新日期:2002-01-01 00:00:00

  • Highlights in muscle relaxants.

    abstract::The aim of this article is to provide an overview on neuromuscular blocking agents and a rational selection of the most appropriate agents, along with pharmacological and pharmacoeconomic considerations on neuromuscular blockers and their antagonists. Neuromuscular blocking agents are used during anesthesia to facilit...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.12.1833

    authors: Leykin Y,Pellis T,Vincenti E

    更新日期:2006-12-01 00:00:00

  • Health economic evaluation: why? When? How?

    abstract::Advances in research and better understanding of the pathophysiology of diseases have resulted in an increase in the number of available health interventions that compete for finite public resources. Explicit choices must therefore be made about funding. ...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2013.865872

    authors: Kobelt G

    更新日期:2013-12-01 00:00:00

  • Current state-of-art of the application of serum neurofilaments in multiple sclerosis diagnosis and monitoring.

    abstract:INTRODUCTION:Neurodegenerative processes occur from the beginning of multiple sclerosis, contribute to irreversible clinical disability and are only partially addressed by current disease-modifying therapies. Reliable quantification of neuro-axonal damage may contribute to improve the assessment of disease activity and...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章

    doi:10.1080/14737175.2020.1760846

    authors: Preziosa P,Rocca MA,Filippi M

    更新日期:2020-08-01 00:00:00

  • Epilepsy treatment by sacrificing vitamin D.

    abstract::Epilepsy is one of the most common neurologic disorders in childhood that often requires long term treatment with antiepileptic drugs. Both antiepileptic treatment and the comorbidities associated with epilepsy have a negative impact on bone health in growing children. Given the fact that vitamin D deficiency is a maj...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2014.905742

    authors: Cebeci AN,Ekici B

    更新日期:2014-05-01 00:00:00

  • Neurostimulation in primary headache syndromes.

    abstract::Neurostimulation therapy involves the use of peripheral or central nerve electrical stimulation approaches for the treatment of medically intractable headache. Currently, for peripheral stimulation the main approach is that of occipital nerve stimulation, while for central stimulation deep-brain approaches with the ta...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.7.12.1785

    authors: Goadsby PJ

    更新日期:2007-12-01 00:00:00

  • Clinical application of C-reactive protein in stroke prevention: bright and dark sides of the moon.

    abstract::In different study populations, several studies have shown that modest C-reactive protein elevation, in the range of apparently healthy individuals, is a strong predictor of future vascular events. Willcox and colleagues summarize the epidemiological and clinical observations that have led to the enthusiastic suggesti...

    journal_title:Expert review of neurotherapeutics

    pub_type: 评论,杂志文章,评审

    doi:10.1586/14737175.4.4.613

    authors: Di Napoli M,Papa F

    更新日期:2004-07-01 00:00:00

  • Internet-supported versus face-to-face cognitive behavior therapy for depression.

    abstract::Major depression and depressive symptoms are highly prevalent and there is a need for different forms of psychological treatments that can be delivered from a distance at a low cost. In the present review the authors contrast face-to-face and Internet-delivered cognitive behavior therapy (ICBT) for depression. A total...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,meta分析,评审

    doi:10.1586/14737175.2015.1125783

    authors: Andersson G,Topooco N,Havik O,Nordgreen T

    更新日期:2016-01-01 00:00:00

  • Response of gait deficits to neuromuscular electrical stimulation for stroke survivors.

    abstract::Persistent gait deficits after stroke can cause falls, elevated energy cost and poor endurance. Coordination impairment is an underlying cause of gait deficits. Few efficacious interventions have been described that have targeted and measured restoration of coordinated gait components. Neuromuscular electrical stimula...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.6.10.1511

    authors: Daly JJ

    更新日期:2006-10-01 00:00:00

  • Retinoic acid as a therapeutic option in Alzheimer's disease: a focus on cholinergic restoration.

    abstract::Retinoic acid is a potent cell differentiating factor, which through its nuclear receptors affects a vast range of promoter sites in brain neuronal and glial cells in every step of embryonic and postnatal life. Its capacities, facilitating maturation of neurotransmitter phenotype in different groups of neurons, pave t...

    journal_title:Expert review of neurotherapeutics

    pub_type: 杂志文章,评审

    doi:10.1586/14737175.2015.1008456

    authors: Szutowicz A,Bielarczyk H,Jankowska-Kulawy A,Ronowska A,Pawełczyk T

    更新日期:2015-03-01 00:00:00